The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy

被引：0
|
作者：
Zattarin, E. [1 ]
Manglaviti, S. [1 ]
Galli, E. [1 ]
Apollonio, G. [1 ]
Beninato, T. [1 ]
Mazzeo, L. [1 ]
Massa, G. [1 ]
Bottiglieri, A. [1 ]
Ganzinelli, M. [1 ]
Proto, C. [1 ]
Ferrara, R. [1 ]
Prelaj, A. [1 ]
Galli, G. [1 ]
De Toma, A. [1 ]
Brambilla, M. [1 ]
Occhipinti, M.
Garassino, M. C. C. [2 ]
De Braud, F. G. M. [1 ]
Lo Russo, G. [1 ]
机构：
[1] Ist Nazl Tumori Milano Fondazione IRCCS, Dept Oncol Med, Milan, Italy
[2] Univ Chicago, Dept Hematol Oncol, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1913
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1311P
引用
收藏
页码：S1010 / S1011
页数：2
相关论文
共 50 条
  • [1] The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
    Rocco, Danilo
    Della Gravara, Luigi
    Battiloro, Ciro
    Gridelli, Cesare
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (07) : 561 - 568
  • [2] The Role of Neoadjuvant Chemo-Immunotherapy in Unresectable Non-Small Cell Lung Cancer
    Oh, M.
    Davis, A.
    Lentz, R.
    Peterman, N.
    Robertson, A.
    Srivas, R.
    Lambert, N.
    Wilson, T.
    Tezcan, H.
    Bharat, A.
    Chae, Y. K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S947 - S948
  • [3] Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?
    Casaluce, Francesca
    Gridelli, Cesare
    EXPERT OPINION ON EMERGING DRUGS, 2023, 28 (02) : 121 - 127
  • [4] The Promising role of Chemo-Immunotherapy in Non-Small Cell Lung Cancer Neoadjuvant Setting
    Bote, H.
    Modrego, A.
    Jimenez-Aguilar, E.
    Mazarico, J. M.
    Nunez-Sobrino, J. A.
    Iglesias, L. C.
    Baena, J.
    Zugazagoitia, J.
    Ponce-Aix, S.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S369 - S370
  • [5] Chemo-immunotherapy A new option for non-small cell lung cancer
    Vitale, Giovanni
    Abbruzzese, Alberto
    Tonini, Giuseppe
    Santini, Daniele
    CANCER BIOLOGY & THERAPY, 2009, 8 (06) : 503 - 504
  • [6] Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer
    Mei, Lihong
    Zhang, Zhihua
    Li, Xushuo
    Yang, Ying
    Qi, Ruixue
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [7] Radiomics nomogram for predicting chemo-immunotherapy efficiency in advanced non-small cell lung cancer
    Jin, Hua
    Wang, Yuchao
    Li, Xushuo
    Yang, Ying
    Qi, Ruixue
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [8] Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer
    Shafique, Michael
    Tanvetyanon, Tawee
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (03) : 225 - 232
  • [9] Plasma lipidomics profiling in predicting the chemo-immunotherapy response in advanced non-small cell lung cancer
    Jiang, Hui
    Li, Xu-Shuo
    Yang, Ying
    Qi, Rui-Xue
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
    Pellini, Bruna
    Madison, Russell W.
    Childress, Merrida A.
    Miller, Shoshana T.
    Gjoerup, Ole
    Cheng, Jason
    Huang, Richard S. P.
    Krainock, Michael
    Gupta, Pratyush
    Zou, Wei
    Shames, David S.
    Moshkevich, Solomon
    Ballinger, Marcus
    Liu, Minetta C.
    Young, Amanda
    Srivastava, Minu K.
    Oxnard, Geoffrey R.
    Socinski, Mark A.
    CLINICAL CANCER RESEARCH, 2023, 29 (22) : 4596 - 4605
12345